SLAMF7 and Miyoshi myopathy: Elotuzumab is a humanized, IgG1 anti-SLAMF7 monoclonal antibody that functions to activate SLAMF7+ NK cells directly towards SLAMF7+ MM cells and induces dose-dependent ADCC similar to Daratumumab without cytotoxicity to autologous SLAMF7+ NK cells [47,48].